Boiron Enters Partnership with Panaxia Malta on Medical Cannabis
Boiron Laboratories has announced the signing of an agreement with Panaxia Malta, specializing in the research and development of medical cannabis. This partnership follows an operational collaboration within the framework of the French experiment conducted by the ANSM.
Strategic Partnership and Future Opportunities
Boiron and Panaxia Malta have entered into a partnership that includes an option, exercisable from 2029, for Boiron to take a majority stake in the capital of Panaxia Malta. This option follows a successful collaboration in which Boiron handled the distribution of Panaxia's medications as part of the French experiment on assessing the relevance and feasibility of making medical cannabis available in France, conducted by the National Agency for the Safety of Medicines and Health Products (ANSM).
Financial Terms and Expansion Plans
The option is granted in exchange for a payment that could amount up to €3.2 million. According to Boiron, this option should allow Panaxia to continue its development in European countries where medical cannabis is authorized. Currently, 21 out of 27 countries within the European Union have already legislated in favor of its marketing.
Implications for the European Therapeutic Landscape
The partnership occurs in a therapeutic field that is becoming increasingly structured at the European level, where the regulatory framework for medical cannabis is progressively being established.
